01_Priority Review and Verification Route
-
Upload
william-chandra -
Category
Documents
-
view
7 -
download
2
description
Transcript of 01_Priority Review and Verification Route
![Page 1: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/1.jpg)
All Rights Reserved 2008 Health Sciences Authority | 1
![Page 2: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/2.jpg)
All Rights Reserved 2008 Health Sciences Authority | 2
Priority Review & Verification Route
Agnes ChanSenior Regulatory Specialist
Pharmaceuticals & Biologics BranchTherapeutics Products Division
Health Products Regulation GroupHealth Sciences Authority
![Page 3: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/3.jpg)
All Rights Reserved 2008 Health Sciences Authority | 3
Overview
• New initiativePriority Review
• UpdateVerification Route
![Page 4: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/4.jpg)
All Rights Reserved 2008 Health Sciences Authority | 4
Priority Review
Pg 32
![Page 5: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/5.jpg)
All Rights Reserved 2008 Health Sciences Authority | 5
Background
• “First-in first-out” queue system for evaluation of drug applications
• Three evaluation routes:
1. Full2. Abridged3. Verification
![Page 6: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/6.jpg)
All Rights Reserved 2008 Health Sciences Authority | 6
Evaluation Routes
Approved by one drug regulatory agency
Verification based on fullassessment report by reference regulatory agency.
Full
Abridged
VerificationApproved by two reference agencies
No prior approval by any drug regulatory agency
Timeline: 60 working days
Full quality, non-clinical, & clinical data.
Timeline: 270 working days
Full quality data and Phase II & III clinical data. Timeline: 180
working days
![Page 7: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/7.jpg)
All Rights Reserved 2008 Health Sciences Authority | 7
Priority Review
• A designation system that allows an application to be moved to the front of the evaluation queue
• i.e. it allows an application to bypass the queuing system
![Page 8: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/8.jpg)
All Rights Reserved 2008 Health Sciences Authority | 8
Evaluation Routes
Approved by one drug regulatory agency
Verification based on fullassessment report by reference regulatory agency.
Full
Abridged
VerificationApproved by two reference agencies
No prior approval by any drug regulatory agency
Timeline: 60 working days
Full quality, non-clinical, & clinical data.
Timeline: 270 working days
Full quality data and Phase II & III clinical data. Timeline: 180
working days
![Page 9: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/9.jpg)
All Rights Reserved 2008 Health Sciences Authority | 9
Qualifying Criteria
• The drug is intended for a serious life-threatening condition, and
• The drug demonstrates potential to address a local unmet medical need
![Page 10: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/10.jpg)
All Rights Reserved 2008 Health Sciences Authority | 10
Definition
“Unmet medical need”
• Absence of treatment option; or
• Lack of safe and effective alternative, and the drug would be a significant improvement compared to available alternatives, as demonstrated by
a) Evidence of increased effectiveness in treatment, prevention, or diagnosis; or
b) Elimination/substantial reduction of treatment-limiting adverse drug reactions
![Page 11: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/11.jpg)
All Rights Reserved 2008 Health Sciences Authority | 11
Local public health concerns
Disease conditions include:• Cancers
• Infectious diseases: Dengue, tuberculosis, hepatitis, malaria
![Page 12: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/12.jpg)
All Rights Reserved 2008 Health Sciences Authority | 12
Justification
1. How serious is the disease?• Seriousness of the disease condition, local &
worldwide mortality rates, anticipated morbidity and debilitation as a consequence of the disease
2. What is the clinical relevance in the local population?
• Local epidemiology data & requests through “named-patient” exemption
![Page 13: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/13.jpg)
All Rights Reserved 2008 Health Sciences Authority | 13
Justification
3. Is there clinical evidence of unmet medical need?
• Unmet needs, available treatment options and inadequacy of available therapies
4. How is the drug going to address the identified unmet medical need?
• Extent to which the product is expected to have a major impact on medical practice, its major benefit, and unmet medical needs can be addressed
![Page 14: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/14.jpg)
All Rights Reserved 2008 Health Sciences Authority | 14
Justification
5. What is the scientific basis?
• The strength of evidence supporting the claims of addressing unmet needs, or, of significant improvement compared to available treatment
![Page 15: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/15.jpg)
All Rights Reserved 2008 Health Sciences Authority | 15
Request for priority review
• Written request with justification to be submitted at the point of filing of application
• Applicant will be informed of the outcome at the point of acceptance of application after screening
![Page 16: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/16.jpg)
All Rights Reserved 2008 Health Sciences Authority | 16
Ultimately, we want to…
• Facilitate timely access to effective drug treatment for serious life-threatening diseases where there is an unmet medical need
• Ensure a fair evaluation queue system and avoid any unjustified “queue jumping”
![Page 17: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/17.jpg)
All Rights Reserved 2008 Health Sciences Authority | 17
Verification Route
![Page 18: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/18.jpg)
All Rights Reserved 2008 Health Sciences Authority | 18
Background
• Streamline the eligibility criteria, timeline & documentary requirements for verification route
• Widen the scope to allow greater flexibility and effective use of this route
• Enhance clarity and minimize inconsistency
![Page 19: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/19.jpg)
All Rights Reserved 2008 Health Sciences Authority | 19
Current approach
# Reference agencies: EMEA, US FDA, Health Canada, MHRA, TGA* TGA as sole reference agency
90 WDs90 WDs120 WDs
1 RA*• Clinical & Quality• Clinical only
60 WDs60 WDs90 WDs
2 RAs• Clinical & Quality• Clinical only
MAV-1NDANo. of RA# approvals
![Page 20: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/20.jpg)
All Rights Reserved 2008 Health Sciences Authority | 20
Key updates• Approval by at least two reference agencies
to ensure consistency in regulatory decision
• Eligibility extends to MAV-1 applications for biologic drugs
• Standard processing timeline: 60 working days (see appendix 1)
• Require both clinical & quality assessment reports to enable effective verification process
Pg 10,33,55
![Page 21: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/21.jpg)
All Rights Reserved 2008 Health Sciences Authority | 21
Streamlined approach
60 WDs60 WDs• Clinical & Quality reports
MAV-1NDA2 RAs# approvals
# Reference agencies: EMEA, US FDA, Health Canada, MHRA, TGA
![Page 22: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/22.jpg)
All Rights Reserved 2008 Health Sciences Authority | 22
• To facilitate applicants to obtain unredactedreports from FDA for submission via verification route:
Applicant may submit request for unredactedreports through HSARequest to be submitted in a prescribed formatSponsor authorization form available upon requestReports to be sent directly to HSA in 4-6 weeks (possible to raise request at pre-submission meeting prior to actual submission)
![Page 23: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/23.jpg)
All Rights Reserved 2008 Health Sciences Authority | 23
Other clarification
• Assessment report should include all annexes and Q&As
• Quality dossier should include:Initial dossier submitted to the primary reference agencyAll reports and/or documents pertaining to post-approval variations approved by the primary reference agency
![Page 24: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/24.jpg)
All Rights Reserved 2008 Health Sciences Authority | 24
Ultimately, we want to…
• Optimize the use of this route
• Facilitate application submission
• Enhance evaluation efficiency
![Page 25: 01_Priority Review and Verification Route](https://reader030.fdocuments.in/reader030/viewer/2022032623/55cf9bee550346d033a7e6d8/html5/thumbnails/25.jpg)
All Rights Reserved 2008 Health Sciences Authority | 25
Thank You